{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-064516","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.948941+00:00","generated_at":"2026-06-12T02:19:42.836255+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"INmune Bio Q2 net loss $6.5M; XPro™ AD trial enrolling; INKmune™ IND cleared","bullets":["Net loss $6.5M vs $6.8M YoY; R&D $4.1M; G&A $2.3M; cash $47.8M at June 30, 2023.","XPro™ Phase II Early AD trial enrolling; FDA pathway to lift clinical hold before end-2023.","New MRI gray matter biomarker data from XPro™ presented at AAIC July 2023.","INKmune™ IND cleared for Phase I/II in mCRPC; first patient enrollment expected Q4 2023.","Top-line XPro™ AD results anticipated late 2024; LAUREL trial opened third site in Greece."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-064516","json":"https://secwatch.observer/filing/0001213900-23-064516.json","markdown":"https://secwatch.observer/filing/0001213900-23-064516.md","text":"https://secwatch.observer/filing/0001213900-23-064516.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390023064516/0001213900-23-064516-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390023064516/ea183062-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:19:42.836255+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"865a9cbb16e10e7cc0a46d9718f3899a22d1057d","claim":"Inmune Bio, Inc. reported financial results for quarter ended June 30, 2023.","evidence_excerpt":"On August 7, 2023, INmune Bio Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390023064516/0001213900-23-064516-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}